1. Home
  2. ISPR vs ACRV Comparison

ISPR vs ACRV Comparison

Compare ISPR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ispire Technology Inc.

ISPR

Ispire Technology Inc.

BUY

Current Price

$1.48

Market Cap

85.5M

Sector

Health Care

ML Signal

BUY

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.82

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISPR
ACRV
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.5M
74.0M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
ISPR
ACRV
Price
$1.48
$1.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$4.90
★ $11.50
AVG Volume (30 Days)
15.8K
★ 251.0K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 15.94
15.13
EPS
★ N/A
N/A
Revenue
★ $96,014,610.00
N/A
Revenue This Year
$16.14
N/A
Revenue Next Year
$8.92
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.01
$1.27
52 Week High
$3.87
$3.56

Technical Indicators

Market Signals
Indicator
ISPR
ACRV
Relative Strength Index (RSI) 51.72 38.70
Support Level $1.41 $1.61
Resistance Level $1.65 $2.21
Average True Range (ATR) 0.12 0.11
MACD 0.01 -0.03
Stochastic Oscillator 43.25 15.47

Price Performance

Historical Comparison
ISPR
ACRV

About ISPR Ispire Technology Inc.

Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: